Last checked at 29 Aug 2023 07:00
RNS Reach
29 August 2023
Diaceutics launches daily alerts for DXRX platform
Daily alerts will enable pharma clients to identify patients previously not receiving the most appropriate treatment due to lack of timely data
Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, is pleased to announce an important and innovative upgrade to its DXRX platform which sees the Company's DXRX Signal product now providing alerts on a daily basis. This ground-breaking innovation will provide Diaceutics' customers with even more timely data to identify patients who would benefit from their therapies and improve their commercial success. For patients, it means their chances of receiving the optimal therapy within the window of effectiveness is significantly improved.
DXRX Signal utilizes real-world data collected from a diverse network of over ~500 labs, encompassing academic, community, and commercial facilities. This comprehensive data pool ensures supply chain reliability and encompasses both geographical and clinical diversity. For Diaceutics' customers, this translates into extensive coverage across a spectrum of medical conditions, including oncology, rare diseases, auto-immune disorders, cardiovascular and infectious diseases.
DXRX Signal has identified over 46,000 patients so far in 2023 for its biopharma clients.
Building upon the foundation of DXRX Signal, Diaceutics has introduced this pivotal enhancement. These alerts, now available on a daily basis, empower Diaceutics' customers with even timelier insights as they deploy products to pinpoint patients and elevate their commercial success. This innovation equips healthcare professionals with crucial data on a daily basis, and within days of a positive test result. With increased timely access to diagnostic information, physicians can be engaged precisely during the treatment decision window, ensuring the most effective drugs or therapies are offered promptly to patients.
In 2022, the 'Practice Gaps Study' highlighted the existence of seven distinct clinical practice gaps. These gaps collectively contributed to a concerning statistic: 64.4% of cancer patients did not receive the appropriate targeted therapy, of which, 29.2% of patients were lost at the critical treatment decision juncture of their medical journey. DXRX Signal specifically targets this cohort of patients, previously not receiving the most appropriate treatment due to lack of timely data.
Available only through the Diaceutics platform, DXRX Signal utilizes our lab data to identify physicians with a patient who has tested positive for a specific biomarker of interest, which may be eligible for therapy. This signal is seamlessly integrated within a customers' operations within as little as 48 hours of the positive test result. From this, they are able to target that physician with a well-informed engagement before a treatment decision has been made so that they can offer a more effective drug or therapy sooner; a key goal for all involved in precision medicine.
Jordan Clark, Chief Commercial Officer of Diaceutics plc, commented: "We recognize the critical importance of engaging physicians during the treatment decision window. By utilizing DXRX Signal, we empower our clients to capitalise on this pivotal moment, ultimately reducing patient losses during this vital stage - the largest 'practice gap.' This enhancement not only increases awareness and biomarker-precision medicine association but also ensures patients receive the precise treatments they deserve, fostering superior clinical outcomes."
Peter Keeling, Chief Executive Officer of Diaceutics plc, commented: "We are breaking new ground with DXRX Signal. This data has simply not been accessible previously to pharma, which we believe is one of the reasons such a worryingly high proportion of patients who could benefit from precision medicine are not receiving it in time. In 2023, we have so far identified over 46,000 patients for whom a specific medicine could change their clinical outcome and we will continue to innovate to ensure that that number increases minute by minute, hour by hour."
Enquiries:
Diaceutics PLC | Tel: +44 (0)28 9040 6500 |
Peter Keeling, Chief Executive Officer Ryan Keeling, Chief Innovation Officer Nick Roberts, Chief Financial Officer | investorrelations@diaceutics.com |
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison | |
Nick Harland Kate Hanshaw | |
Alma PR | Tel: +44 (0)20 3405 0205 |
Caroline Forde | diaceutics@almapr.co.uk |
Matthew Young | |
Kinvara Verdon |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by our proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.